Ticlopidine, Platelets and Vascular Disease:
Blood platelets lack a nucleus. As a result their life span is short and they cannot reproduce themselves. Platelets share these qualities with the red blood cell. Plate lets and red blood cells, nevertheless, serve vital roles in the body. One major function of the platelet is its capacity to aggr...
Gespeichert in:
Weitere Verfasser: | , |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
New York, NY
Springer New York
1993
|
Schlagworte: | |
Online-Zugang: | UBR01 Volltext |
Zusammenfassung: | Blood platelets lack a nucleus. As a result their life span is short and they cannot reproduce themselves. Platelets share these qualities with the red blood cell. Plate lets and red blood cells, nevertheless, serve vital roles in the body. One major function of the platelet is its capacity to aggregate and thereby initiate intravas cular coagulation which often underlies such major diseases as myocardial infarc tion, cerebral infarction, and pulmonary embolism. For this reason in recent years, medical attention has been directed to drugs that inhibit platelet aggregation. Aspirin was the first drug to be proven effective in this area. Since then other drugs that share aspirin's fundamental biochemical action, inhibition of platelet cyclooxygenase, have also been studied. Very recently, ticlopidine, the first of what promises to be a new class of drugs inhibiting platelet aggregation and coagulation via an entirely different biochemical mechanism, has been exten sively studied and clinically shown to be as effective or more effective than aspirin in the prevention of ischemic cardiovascular and cerebrovascular disease |
Beschreibung: | 1 Online-Ressource (162 p) |
ISBN: | 9781461383062 |
DOI: | 10.1007/978-1-4613-8306-2 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV046145956 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 190905s1993 |||| o||u| ||||||eng d | ||
020 | |a 9781461383062 |9 978-1-4613-8306-2 | ||
024 | 7 | |a 10.1007/978-1-4613-8306-2 |2 doi | |
035 | |a (ZDB-2-SME)978-1-4613-8306-2 | ||
035 | |a (OCoLC)1118997029 | ||
035 | |a (DE-599)BVBBV046145956 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
049 | |a DE-355 | ||
082 | 0 | |a 616.12 |2 23 | |
084 | |a XI 4503 |0 (DE-625)153007:12909 |2 rvk | ||
245 | 1 | 0 | |a Ticlopidine, Platelets and Vascular Disease |c edited by William K. Hass, J. Donald Easton |
264 | 1 | |a New York, NY |b Springer New York |c 1993 | |
300 | |a 1 Online-Ressource (162 p) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
520 | |a Blood platelets lack a nucleus. As a result their life span is short and they cannot reproduce themselves. Platelets share these qualities with the red blood cell. Plate lets and red blood cells, nevertheless, serve vital roles in the body. One major function of the platelet is its capacity to aggregate and thereby initiate intravas cular coagulation which often underlies such major diseases as myocardial infarc tion, cerebral infarction, and pulmonary embolism. For this reason in recent years, medical attention has been directed to drugs that inhibit platelet aggregation. Aspirin was the first drug to be proven effective in this area. Since then other drugs that share aspirin's fundamental biochemical action, inhibition of platelet cyclooxygenase, have also been studied. Very recently, ticlopidine, the first of what promises to be a new class of drugs inhibiting platelet aggregation and coagulation via an entirely different biochemical mechanism, has been exten sively studied and clinically shown to be as effective or more effective than aspirin in the prevention of ischemic cardiovascular and cerebrovascular disease | ||
650 | 4 | |a Cardiology | |
650 | 4 | |a Pharmacology/Toxicology | |
650 | 4 | |a Cardiology | |
650 | 4 | |a Toxicology | |
650 | 0 | 7 | |a Ticlopidin |0 (DE-588)4131352-5 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Thrombozyt |0 (DE-588)4059964-4 |2 gnd |9 rswk-swf |
650 | 0 | 7 | |a Gefäßkrankheit |0 (DE-588)4071631-4 |2 gnd |9 rswk-swf |
689 | 0 | 0 | |a Ticlopidin |0 (DE-588)4131352-5 |D s |
689 | 0 | 1 | |a Thrombozyt |0 (DE-588)4059964-4 |D s |
689 | 0 | 2 | |a Gefäßkrankheit |0 (DE-588)4071631-4 |D s |
689 | 0 | |5 DE-604 | |
700 | 1 | |a Hass, William K. |4 edt | |
700 | 1 | |a Easton, J. Donald |4 edt | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461383086 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780387940090 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461383079 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4613-8306-2 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-SME | ||
940 | 1 | |q ZDB-2-SME_1990/2004 | |
999 | |a oai:aleph.bib-bvb.de:BVB01-031526141 | ||
966 | e | |u https://doi.org/10.1007/978-1-4613-8306-2 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1804180483267887104 |
---|---|
any_adam_object | |
author2 | Hass, William K. Easton, J. Donald |
author2_role | edt edt |
author2_variant | w k h wk wkh j d e jd jde |
author_facet | Hass, William K. Easton, J. Donald |
building | Verbundindex |
bvnumber | BV046145956 |
classification_rvk | XI 4503 |
collection | ZDB-2-SME |
ctrlnum | (ZDB-2-SME)978-1-4613-8306-2 (OCoLC)1118997029 (DE-599)BVBBV046145956 |
dewey-full | 616.12 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 616 - Diseases |
dewey-raw | 616.12 |
dewey-search | 616.12 |
dewey-sort | 3616.12 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
doi_str_mv | 10.1007/978-1-4613-8306-2 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03095nmm a2200541zc 4500</leader><controlfield tag="001">BV046145956</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1993 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461383062</subfield><subfield code="9">978-1-4613-8306-2</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4613-8306-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4613-8306-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118997029</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145956</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 4503</subfield><subfield code="0">(DE-625)153007:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ticlopidine, Platelets and Vascular Disease</subfield><subfield code="c">edited by William K. Hass, J. Donald Easton</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">Springer New York</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (162 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Blood platelets lack a nucleus. As a result their life span is short and they cannot reproduce themselves. Platelets share these qualities with the red blood cell. Plate lets and red blood cells, nevertheless, serve vital roles in the body. One major function of the platelet is its capacity to aggregate and thereby initiate intravas cular coagulation which often underlies such major diseases as myocardial infarc tion, cerebral infarction, and pulmonary embolism. For this reason in recent years, medical attention has been directed to drugs that inhibit platelet aggregation. Aspirin was the first drug to be proven effective in this area. Since then other drugs that share aspirin's fundamental biochemical action, inhibition of platelet cyclooxygenase, have also been studied. Very recently, ticlopidine, the first of what promises to be a new class of drugs inhibiting platelet aggregation and coagulation via an entirely different biochemical mechanism, has been exten sively studied and clinically shown to be as effective or more effective than aspirin in the prevention of ischemic cardiovascular and cerebrovascular disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Ticlopidin</subfield><subfield code="0">(DE-588)4131352-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Thrombozyt</subfield><subfield code="0">(DE-588)4059964-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Gefäßkrankheit</subfield><subfield code="0">(DE-588)4071631-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Ticlopidin</subfield><subfield code="0">(DE-588)4131352-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Thrombozyt</subfield><subfield code="0">(DE-588)4059964-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Gefäßkrankheit</subfield><subfield code="0">(DE-588)4071631-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hass, William K.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Easton, J. Donald</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461383086</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780387940090</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461383079</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4613-8306-2</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526141</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4613-8306-2</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV046145956 |
illustrated | Not Illustrated |
indexdate | 2024-07-10T08:36:29Z |
institution | BVB |
isbn | 9781461383062 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526141 |
oclc_num | 1118997029 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | 1 Online-Ressource (162 p) |
psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
publishDate | 1993 |
publishDateSearch | 1993 |
publishDateSort | 1993 |
publisher | Springer New York |
record_format | marc |
spelling | Ticlopidine, Platelets and Vascular Disease edited by William K. Hass, J. Donald Easton New York, NY Springer New York 1993 1 Online-Ressource (162 p) txt rdacontent c rdamedia cr rdacarrier Blood platelets lack a nucleus. As a result their life span is short and they cannot reproduce themselves. Platelets share these qualities with the red blood cell. Plate lets and red blood cells, nevertheless, serve vital roles in the body. One major function of the platelet is its capacity to aggregate and thereby initiate intravas cular coagulation which often underlies such major diseases as myocardial infarc tion, cerebral infarction, and pulmonary embolism. For this reason in recent years, medical attention has been directed to drugs that inhibit platelet aggregation. Aspirin was the first drug to be proven effective in this area. Since then other drugs that share aspirin's fundamental biochemical action, inhibition of platelet cyclooxygenase, have also been studied. Very recently, ticlopidine, the first of what promises to be a new class of drugs inhibiting platelet aggregation and coagulation via an entirely different biochemical mechanism, has been exten sively studied and clinically shown to be as effective or more effective than aspirin in the prevention of ischemic cardiovascular and cerebrovascular disease Cardiology Pharmacology/Toxicology Toxicology Ticlopidin (DE-588)4131352-5 gnd rswk-swf Thrombozyt (DE-588)4059964-4 gnd rswk-swf Gefäßkrankheit (DE-588)4071631-4 gnd rswk-swf Ticlopidin (DE-588)4131352-5 s Thrombozyt (DE-588)4059964-4 s Gefäßkrankheit (DE-588)4071631-4 s DE-604 Hass, William K. edt Easton, J. Donald edt Erscheint auch als Druck-Ausgabe 9781461383086 Erscheint auch als Druck-Ausgabe 9780387940090 Erscheint auch als Druck-Ausgabe 9781461383079 https://doi.org/10.1007/978-1-4613-8306-2 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Ticlopidine, Platelets and Vascular Disease Cardiology Pharmacology/Toxicology Toxicology Ticlopidin (DE-588)4131352-5 gnd Thrombozyt (DE-588)4059964-4 gnd Gefäßkrankheit (DE-588)4071631-4 gnd |
subject_GND | (DE-588)4131352-5 (DE-588)4059964-4 (DE-588)4071631-4 |
title | Ticlopidine, Platelets and Vascular Disease |
title_auth | Ticlopidine, Platelets and Vascular Disease |
title_exact_search | Ticlopidine, Platelets and Vascular Disease |
title_full | Ticlopidine, Platelets and Vascular Disease edited by William K. Hass, J. Donald Easton |
title_fullStr | Ticlopidine, Platelets and Vascular Disease edited by William K. Hass, J. Donald Easton |
title_full_unstemmed | Ticlopidine, Platelets and Vascular Disease edited by William K. Hass, J. Donald Easton |
title_short | Ticlopidine, Platelets and Vascular Disease |
title_sort | ticlopidine platelets and vascular disease |
topic | Cardiology Pharmacology/Toxicology Toxicology Ticlopidin (DE-588)4131352-5 gnd Thrombozyt (DE-588)4059964-4 gnd Gefäßkrankheit (DE-588)4071631-4 gnd |
topic_facet | Cardiology Pharmacology/Toxicology Toxicology Ticlopidin Thrombozyt Gefäßkrankheit |
url | https://doi.org/10.1007/978-1-4613-8306-2 |
work_keys_str_mv | AT hasswilliamk ticlopidineplateletsandvasculardisease AT eastonjdonald ticlopidineplateletsandvasculardisease |